For instance, a study investigating this therapy for hemophilia in nonhuman primates revealed that, in addition to administering mycophenolate mofetil and rapamycin, only a delayed delivery of antithymocyte globulin 5 weeks post‐AAV administration effectively suppressed the development of human factor IX antibodies. The gene discussed is F9; the disease is hemophilia.